由Gefitinib引发的截肢:一种不寻常的临床表现
Lihua Tao1, Jiaqi Ruan2, Xiaodong Chu3
1Department of Endocrinology and Rheumatology, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHN.
吉菲提尼布是一种针对肺癌的向疗法,可以导致罕见但严重的血管事件. 一名患有糖尿病的患者经历了gefitinib治疗后的下肢截肢,突出了脆弱人群的风险.
科学领域:
- 在瘤学瘤学.
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 格菲提尼布是一种氨酸激酶抑制剂,向表皮生长因子受体,用于治疗肺癌和其他固体瘤.
- 常见的不良反应包括皮肤和胃肠道问题,罕见的血管事件如心肌梗塞和中风.
- 患有并发症的糖尿病患者对向癌症治疗具有复杂的特征.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
